Another flop for Xeljanz

Discussion in 'Pfizer' started by Anonymous, Oct 11, 2013 at 3:18 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    only matched Enbrel efficacy in psoriasis at the dose that the FDA didn't approve! Add that to the fact that most Derms agree that Enbrel doesn't even work as well as Humira. Where is the market for this supposed "blockbuster"?
     

  2. Anonymous

    Anonymous Guest

    Flip. Flop. Dead. Fish.
     
  3. Anonymous

    Anonymous Guest

    Xeldance time!

    Your gal,

    Humira
     
  4. Anonymous

    Anonymous Guest

    "serious side-effects". Exubera up and comer.
     
  5. Anonymous

    Anonymous Guest

    We had all better hope not! We are counting on this drug to replace Celebrex volume.
     
  6. Anonymous

    Anonymous Guest

    Thanks, Amgen
     
  7. Anonymous

    Anonymous Guest

    Looks like we will never get our 10mg out due to toxicity
     
  8. Anonymous

    Anonymous Guest

    Thanks Pfizer, who stole the Enbrel from Wyeth for this study.
     
  9. Anonymous

    Anonymous Guest

    Is the Charlotte DM still going to be around. I have heard mixed reviews.
     
  10. Anonymous

    Anonymous Guest

    Celgene calling... No one great is going to be around soon. More money, better benefits, greater company, higher rewards, fantastic product.
     
  11. Anonymous

    Anonymous Guest

    Come on over if you like Gulag style micromanagement.

    Jay-Ed-Herb...that says it all
     
  12. Anonymous

    Anonymous Guest

    The manager in Buffalo is a 26yo woman with NO management experience, New England manager former Humira rep with NO management experience. So they won't be hiring any superstars, just friends who don't know their ass from their elbow getting paid big salary but the launch will be a disaster you watch.
     
  13. Anonymous

    Anonymous Guest

    Wow! Remember when a career had no limits at Pfizer? To be limitless, again.
     
  14. Anonymous

    Anonymous Guest

    I applied with Celgene. Wish they would call me. Talked with two members of the district who have already interviewed and it sounded great. Performance based. Huge bonus the first year. No activity trackers. Create your own call cycle so long as you perform. Stock options every year. Stock actually grows. Hiring people based on energy and enthusiasm, not tenure.

    Everything we should be, but am too busy filling out tracking templates.
     
  15. Anonymous

    Anonymous Guest

    How is management, specifically NC/SC. I have heard mixed reviews about working for him.
     
  16. Anonymous

    Anonymous Guest

    ?
     
  17. Anonymous

    Anonymous Guest

    Is Herb going to be the DM still?
     
  18. Anonymous

    Anonymous Guest

    The drug is not the flop.

    The entire management of it is the flop.

    This company only has loyalty to managers. They can fail repeatedly and stay on with the company while successful sales people get cut left and right.
     
  19. Anonymous

    Anonymous Guest

    well?
     
  20. Anonymous

    Anonymous Guest

    Interviewed with them. It sounds like it will be great for the forst 6-12 months, then when things start to not look too good, the hammers will come down , the honeymoon period will be over and they will be able to turn the districts over rapidly

    There is a reason the DM's have no management experience with that division and they are targeting young, inexperienced reps from other companies. They are looking for a lot of people who are easy to control and do not know any better (sound familiar?)

    Not worth reliving it at another company after already going through it here.